200 related articles for article (PubMed ID: 29557740)
1. PI3K Signaling in Chronic Obstructive Pulmonary Disease: Mechanisms, Targets, and Therapy.
Pirozzi F; Ren K; Murabito A; Ghigo A
Curr Med Chem; 2019; 26(16):2791-2800. PubMed ID: 29557740
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary administration of phosphoinositide 3-kinase inhibitor is a curative treatment for chronic obstructive pulmonary disease by alveolar regeneration.
Horiguchi M; Oiso Y; Sakai H; Motomura T; Yamashita C
J Control Release; 2015 Sep; 213():112-119. PubMed ID: 26160307
[TBL] [Abstract][Full Text] [Related]
3. PI3K signalling in chronic obstructive pulmonary disease and opportunities for therapy.
Moradi S; Jarrahi E; Ahmadi A; Salimian J; Karimi M; Zarei A; Azimzadeh Jamalkandi S; Ghanei M
J Pathol; 2021 Aug; 254(5):505-518. PubMed ID: 33959951
[TBL] [Abstract][Full Text] [Related]
4. Targeting PI3K-p110α Suppresses Influenza Virus Infection in Chronic Obstructive Pulmonary Disease.
Hsu AC; Starkey MR; Hanish I; Parsons K; Haw TJ; Howland LJ; Barr I; Mahony JB; Foster PS; Knight DA; Wark PA; Hansbro PM
Am J Respir Crit Care Med; 2015 May; 191(9):1012-23. PubMed ID: 25751541
[TBL] [Abstract][Full Text] [Related]
5. Identifying Molecular Targets for New Drug Development for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?
Barnes PJ
Semin Respir Crit Care Med; 2015 Aug; 36(4):508-22. PubMed ID: 26238638
[TBL] [Abstract][Full Text] [Related]
6. Emerging pharmaceutical therapies for COPD.
Lakshmi SP; Reddy AT; Reddy RC
Int J Chron Obstruct Pulmon Dis; 2017; 12():2141-2156. PubMed ID: 28790817
[TBL] [Abstract][Full Text] [Related]
7. p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD.
Banerjee A; Koziol-White C; Panettieri R
Curr Opin Pharmacol; 2012 Jun; 12(3):287-92. PubMed ID: 22365729
[TBL] [Abstract][Full Text] [Related]
8. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
9. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease.
To Y; Ito K; Kizawa Y; Failla M; Ito M; Kusama T; Elliott WM; Hogg JC; Adcock IM; Barnes PJ
Am J Respir Crit Care Med; 2010 Oct; 182(7):897-904. PubMed ID: 20224070
[TBL] [Abstract][Full Text] [Related]
10. Therapy for chronic obstructive pulmonary disease in the 21st century.
Donnelly LE; Rogers DF
Drugs; 2003; 63(19):1973-98. PubMed ID: 12962514
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF).
Sala V; Margaria JP; Murabito A; Morello F; Ghigo A; Hirsch E
Curr Heart Fail Rep; 2017 Jun; 14(3):187-196. PubMed ID: 28451983
[TBL] [Abstract][Full Text] [Related]
12. Development of new drugs for COPD.
Barnes PJ
Curr Med Chem; 2013; 20(12):1531-40. PubMed ID: 22963554
[TBL] [Abstract][Full Text] [Related]
13. Biological targets for therapeutic interventions in COPD: clinical potential.
Pelaia G; Vatrella A; Gallelli L; Renda T; Caputi M; Maselli R; Marsico SA
Int J Chron Obstruct Pulmon Dis; 2006; 1(3):321-34. PubMed ID: 18046869
[TBL] [Abstract][Full Text] [Related]
14. Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease.
Barnes PJ
Pharmacol Rev; 2016 Jul; 68(3):788-815. PubMed ID: 27363440
[TBL] [Abstract][Full Text] [Related]
15. Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives.
Vyas P; Vohora D
Curr Drug Targets; 2017; 18(14):1622-1640. PubMed ID: 27739372
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of phosphoinositol 3 kinase and NFκB for the treatment of chronic obstructive pulmonary disease.
Larocca NE; Moreno D; Garmendia JV; De Sanctis JB
Recent Pat Inflamm Allergy Drug Discov; 2011 Sep; 5(3):178-83. PubMed ID: 21827398
[TBL] [Abstract][Full Text] [Related]
17. The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils.
Gupta V; Khan A; Higham A; Lemon J; Sriskantharajah S; Amour A; Hessel EM; Southworth T; Singh D
Int Immunopharmacol; 2016 Jun; 35():155-162. PubMed ID: 27049289
[TBL] [Abstract][Full Text] [Related]
18. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
19. A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease.
Marwick JA; Caramori G; Casolari P; Mazzoni F; Kirkham PA; Adcock IM; Chung KF; Papi A
J Allergy Clin Immunol; 2010 May; 125(5):1146-53. PubMed ID: 20381852
[TBL] [Abstract][Full Text] [Related]
20. Novel drug targets for asthma and COPD: lessons learned from in vitro and in vivo models.
Baker KE; Bonvini SJ; Donovan C; Foong RE; Han B; Jha A; Shaifta Y; Smit M; Johnson JR; Moir LM
Pulm Pharmacol Ther; 2014 Dec; 29(2):181-98. PubMed ID: 24929072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
